NZ725028A - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents

Membrane-adherent self-assembled systems for treatment of ocular disorders

Info

Publication number
NZ725028A
NZ725028A NZ725028A NZ72502815A NZ725028A NZ 725028 A NZ725028 A NZ 725028A NZ 725028 A NZ725028 A NZ 725028A NZ 72502815 A NZ72502815 A NZ 72502815A NZ 725028 A NZ725028 A NZ 725028A
Authority
NZ
New Zealand
Prior art keywords
delivery system
present
liquid crystalline
alcohol
nanoparticles
Prior art date
Application number
NZ725028A
Other languages
English (en)
Inventor
Shikha P Barman
Ritesh V Thekkedath
Koushik Barman
Kevin L Ward
Anne-Marie Cromwick
Original Assignee
Integral Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems Llc filed Critical Integral Biosystems Llc
Publication of NZ725028A publication Critical patent/NZ725028A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
NZ725028A 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders NZ725028A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987012P 2014-05-01 2014-05-01
PCT/US2015/028748 WO2015168523A1 (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Publications (1)

Publication Number Publication Date
NZ725028A true NZ725028A (en) 2019-01-25

Family

ID=54359368

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ725028A NZ725028A (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Country Status (12)

Country Link
US (2) US9901544B2 (cg-RX-API-DMAC7.html)
EP (1) EP3137481B1 (cg-RX-API-DMAC7.html)
JP (1) JP6452725B2 (cg-RX-API-DMAC7.html)
KR (1) KR101890503B1 (cg-RX-API-DMAC7.html)
CN (1) CN106459137B (cg-RX-API-DMAC7.html)
AU (2) AU2015252908B2 (cg-RX-API-DMAC7.html)
CA (1) CA2946373C (cg-RX-API-DMAC7.html)
ES (1) ES2924768T3 (cg-RX-API-DMAC7.html)
MY (1) MY193694A (cg-RX-API-DMAC7.html)
NZ (1) NZ725028A (cg-RX-API-DMAC7.html)
SG (1) SG11201608729RA (cg-RX-API-DMAC7.html)
WO (1) WO2015168523A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266446B1 (en) * 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
JPWO2018230713A1 (ja) * 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3643297A4 (en) * 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR THE TREATMENT OF GLAUCOMA
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
WO2019043169A1 (en) * 2017-09-01 2019-03-07 Murray & Poole Enterprises, Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
JP7056480B2 (ja) * 2017-09-08 2022-04-19 ライオン株式会社 眼科用組成物及び涙液油層安定化剤
CN109316440B (zh) * 2018-09-29 2020-12-29 华中科技大学 一种温敏性液晶纳米水凝胶及其制备方法与应用
DK3870226T3 (da) * 2018-10-24 2023-09-18 Ferring Bv Mukoadhæsive farmaceutiske sammensætninger af kortikosteroider
GB201818043D0 (en) * 2018-11-05 2018-12-19 Waterford Institute Of Tech Artifical Tears
WO2021234548A1 (en) * 2020-05-18 2021-11-25 Max Biology Co. Ltd. Lipid-polymer compositions and methods of use
US11382910B2 (en) * 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
AU2021360121A1 (en) * 2020-10-13 2023-06-22 University Of South Australia Antimicrobial compositions and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP4049216B2 (ja) * 2003-05-09 2008-02-20 ポーラ化成工業株式会社 液晶構造を有する製剤
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050235740A1 (en) * 2004-04-27 2005-10-27 Guido Desie Method to improve the quality of dispersion formulations
CN101005828B (zh) * 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2008011836A2 (es) * 2006-07-25 2008-01-31 Osmotica Corp. Soluciones oftálmicas
JP2010064995A (ja) * 2008-09-12 2010-03-25 Nikko Chemical Co Ltd 外用消炎鎮痛剤組成物
EP2518040B1 (en) * 2009-12-25 2018-10-31 Farnex Incorporated Low-viscosity liquid-crystal compound
CN101773670A (zh) * 2009-12-29 2010-07-14 中山大学 一种液晶药物载体
JP2012017318A (ja) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd 液晶及びそれを含有する皮膚外用剤
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
NZ728721A (en) * 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP3517541B1 (en) * 2012-05-08 2020-07-15 Nicox Ophthalmics, Inc. Polymorphic form of fluticasone propionate

Also Published As

Publication number Publication date
CA2946373A1 (en) 2015-11-05
JP6452725B2 (ja) 2019-01-16
AU2015252908A1 (en) 2016-10-27
AU2018201596A1 (en) 2018-03-29
MY193694A (en) 2022-10-25
US10603273B2 (en) 2020-03-31
US20180185275A1 (en) 2018-07-05
JP2017514843A (ja) 2017-06-08
US20170049697A1 (en) 2017-02-23
KR20160147784A (ko) 2016-12-23
AU2015252908B2 (en) 2017-12-07
ES2924768T3 (es) 2022-10-10
US9901544B2 (en) 2018-02-27
EP3137481B1 (en) 2022-07-06
WO2015168523A1 (en) 2015-11-05
CA2946373C (en) 2018-07-31
KR101890503B1 (ko) 2018-08-21
CN106459137A (zh) 2017-02-22
EP3137481A1 (en) 2017-03-08
CN106459137B (zh) 2019-04-12
EP3137481A4 (en) 2017-12-27
AU2018201596B2 (en) 2020-02-06
SG11201608729RA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
NZ725028A (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
US20230285443A1 (en) Ophthalmic compositions with improved dessication protection and retention
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
JP6832390B2 (ja) 水性液剤
KR20170036058A (ko) 코 적용을 위한 시네올-함유 조성물
JP7055930B2 (ja) 眼科組成物
CN102784416A (zh) 一种新型助分娩凝胶及其制备方法和应用
JP2022079633A (ja) 異物感改善用眼科組成物
WO2010010689A1 (ja) コンタクトレンズ用液剤
TWI712429B (zh) 水性醫藥組成物
JP2017119693A (ja) 眼科用組成物及びその製造方法
CN106178140A (zh) 一种纯天然水溶性人体润滑剂及其制备方法与应用
IT202200021852A1 (it) Composizione liquida oftalmica viscosa comprendente gomme ed estratti naturali
JP2006225323A (ja) 水性外用組成物
JP2006248960A (ja) 水性外用組成物
TW201336527A (zh) 具增強的穩定性之水性藥學組成物
JP6571391B2 (ja) 水性製剤
JP2014136684A (ja) 液剤
HK1226333A1 (en) Compositions and methods for ophthalmic and/or other applications
HK1210589B (en) Aqueous liquid medicine
GR1008261B (el) Συνθεσεις νανοφορεων
UA80243U (ru) Система доставки лекарств

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 3540134, BARMAN, SHIKHA P., 2 BONNIEVALE DRIVEBEDFORD, MASSACHUSETTS 01730, US; 3540135, THEKKEDATH, RITESH V., 335 HUNTINGTON AVENUE, APT #21BOSTON, MASSACHUSETTS 02115, US; 3546668, BARMAN, KOUSHIK, 2 BONNIEVALE DR., BEDFORD, MASSACHUSETTS 01730, US; 3546669, WARD, KEVIN L., 106 CLEREMON AVE., ARLINGTON, MASSACHUSETTS 02476, US; 3546670, CROMWICK, ANNE-MARIE, 11 DONNA RD., SAUGUS, MASSACHUSETTS 01906, US

Effective date: 20161125

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAY 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417